Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Translocation of Proteins into the Mitochondria01:19

Translocation of Proteins into the Mitochondria

Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanomedicines for modulating the gut-brain axis.

Nanomedicine (London, England)·2026
Same author

Hybrid Aminoferrocenes With Nitrate Esters for In Situ Peroxynitrite Generation: Complex Interplay Between Redox Chemistry, NO-Donor Reactivity, and Aminoferrocene Activation Influences In Vitro Anticancer Activity.

Chembiochem : a European journal of chemical biology·2026
Same author

Removal and analysis of foodborne-associated pathogens via peptide functionalized nanoparticles.

Applied microbiology and biotechnology·2026
Same author

Molecular Dioxygen-Mediated Passivation of Electron Traps in n-Type Organic Charge-Transfer Complexes.

Angewandte Chemie (International ed. in English)·2026
Same author

Corrigendum to "GMP-Compliant batch manufacturing of dextran-coated iron oxide nanoparticles: A process development case study" [Biochem. Biophys. Res. Communications 805 (2026) 153336].

Biochemical and biophysical research communications·2026
Same author

A supercharged molecular motor operating by constitutional alteration and proton transfer.

Nature chemistry·2026

Related Experiment Video

Updated: Jul 14, 2026

Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

Copper(II)-Mediated Mitochondria-Targeting in Cancer Cells.

Marlies Körber1, Fabian Halter1, Dina Attia1

  • 1Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU), 91058 Erlangen, Germany.

Journal of Medicinal Chemistry
|July 13, 2026
PubMed
Summary

Researchers developed a novel copper-mediated strategy to target mitochondria in cancer cells. This approach utilizes the elevated copper levels in cancer cells to activate specialized anticancer drugs, enhancing their potency and selectivity.

More Related Videos

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Related Experiment Videos

Last Updated: Jul 14, 2026

Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Area of Science:

  • Mitochondrial targeting
  • Cancer therapy
  • Metal coordination chemistry

Background:

  • Mitochondria are key targets for anticancer drugs due to their role in cell death.
  • Selective targeting of mitochondria remains a significant challenge in cancer treatment.
  • Cancer cells often exhibit altered intracellular metal ion concentrations, such as copper.

Purpose of the Study:

  • To develop a novel strategy for mitochondria-directed anticancer activity using intracellular metal coordination.
  • To exploit elevated copper levels in cancer cells for drug activation and targeting.
  • To investigate the structure-activity relationships of copper-chelating aminoferrocene conjugates.

Main Methods:

  • Functionalization of aminoferrocene drugs with copper(II)-binding ligands.
  • Synthesis and characterization of copper(II) complexes with aminoferrocene conjugates.
  • Evaluation of cytotoxicity and copper(II) dependency in ovarian carcinoma cells.
  • Spectroscopic, magnetic, and mass spectrometric analyses to confirm complex formation.
  • Assessment of mitochondrial accumulation, membrane potential, and reactive oxygen species (ROS) generation.

Main Results:

  • The bipyridine conjugate AFb-L4 showed potent copper(II)-dependent cytotoxicity (IC50 = 29 nM) in ovarian carcinoma cells, with a ~500-fold enhancement upon copper(II) addition.
  • Formation of a 1:1 AFb-L4-Cu(II) complex was confirmed, with no electronic coupling between copper and ferrocene centers.
  • Intracellular copper(II) coordination converted AFb-L4 into a cationic species that localized in mitochondria.
  • Mitochondrial accumulation led to loss of membrane potential, remodeling, and increased mitochondrial ROS generation.
  • Stabilization of copper(II) was critical for activity; a sterically hindered isomer with reduced copper(II) binding was inactive.

Conclusions:

  • Intracellular copper(II) coordination can serve as a trigger for mitochondria-directed drug delivery and activation.
  • This strategy offers a promising approach for selective cancer therapy by exploiting cancer-specific metal ion levels.
  • The developed aminoferrocene-copper conjugates represent a new class of mitochondria-targeting anticancer agents.